Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 4/20 | 0.40 |
| ▸ | CTSL | P07711 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 6/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 6/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6479313 | 1.00 | CTSV (0.40) | CTSVCTSLPOLBOPRD1OPRK1 | |
| SCHEMBL7039596 | 0.96 | CTSV (0.43) | CTSVCTSLPOLBFFAR1PDCD1 | |
| SCHEMBL7039802 | 0.94 | MEN1 (0.41) | CTSVCTSLPOLBFFAR1PDCD1 | |
| SCHEMBL7686827 | 0.92 | CTSV (0.46) | CTSVCTSLPOLBFFAR1PDCD1 | |
| SCHEMBL7036432 | 0.92 | KMT2A (0.41) | CTSVCTSLPOLBFFAR1PDCD1 | |
| SCHEMBL7036429 | 0.92 | KMT2A (0.41) | CTSVCTSLPOLBFFAR1PDCD1 | |
| SCHEMBL6541035 | 0.92 | POLB (0.44) | CTSVCTSLPOLBFFAR1PDCD1 | |
| SCHEMBL6541029 | 0.92 | POLB (0.44) | CTSVCTSLPOLBFFAR1PDCD1 | |
| SCHEMBL7042818 | 0.91 | FFAR1 (0.44) | CTSVCTSLPOLBFFAR1PDCD1 | |
| SCHEMBL11820298 | 0.89 | CTSV (0.41) | CTSVCTSLPOLBOPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-02-24 | — | — | US | disclosed |
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-10-03 | — | — | US | disclosed |
| WO-2002000622-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | WO | disclosed |
| EP-1140849-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000040560-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB1, ADRB2, ADRB3 | CTSV 4425/4885CTSL 3805/4885POLB 2187/4885 |
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB2, ADRB1, ADRB3 | CTSV 4139/4885CTSL 3655/4885POLB 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.